Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma
- 1 January 1990
Abstract
Two cases are reported of patients who developed a hematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and mitomycin C. In one patient, karyotypic abnormalities (−5, 7q-) typical of a therapy induced malignancy were associated with rapid progression of a refractory anemia with excess blasts in transformation to an acute non-lymphocytic leukemia. Intravesical chemotherapy may be associated with a risk of secondary malignancy.This publication has 18 references indexed in Scilit:
- Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelinesEuropean Journal of Cancer and Clinical Oncology, 1987
- Absorption of epi-doxorubicin after intravesical administration of patients with in situ transitional cell carcinoma of the bladderEuropean Journal of Cancer and Clinical Oncology, 1987
- Studies of Mitomycin C Absorption After Intravesical Treatment of Superficial Bladder TumorsJournal of Urology, 1984
- Intravesical Instillation of Adriamycin Early after Transurethral Resection: Measurements of Plasma LevelsEuropean Urology, 1984
- Mitomycin Instillation to Prevent Recurrence of Superficial Bladder CarcinomaEuropean Urology, 1983
- Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes in patients with previously treated malignant diseaseBlood, 1981
- The Use of Intravesical Thio-Tepa in the Management of Non-invasive Carcinoma of the BladderJournal of Urology, 1981
- Intracavitary Doxorubicin Hydrochloride Therapy for Carcinoma in Situ of the BladderJournal of Urology, 1981
- Studies on the Intravesical Action of Topically Administered G 3 H-Doxorubicin Hydrochloride in Men: Plasma Uptake and Tumor PenetrationJournal of Urology, 1980
- Human bone marrow colony growth in agar‐gelJournal of Cellular Physiology, 1970